Magnesium Threonate is Preferred Over Magnesium Glycinate for Insomnia
For insomnia treatment, magnesium threonate (magnesium L-threonate) is the superior choice at 1 gram daily (approximately 144 mg elemental magnesium), as it demonstrates objective improvements in deep and REM sleep stages along with daytime functioning, whereas magnesium glycinate shows only modest subjective benefits.
Critical Context: Guidelines Do Not Support Magnesium as First-Line Treatment
Before discussing magnesium formulations, it's essential to understand that neither magnesium supplement is recommended in clinical practice guidelines for chronic insomnia disorder 1, 2. The 2019 VA/DoD and 2016 American College of Physicians guidelines prioritize cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with short-term pharmacotherapy (low-dose doxepin 3-6 mg or non-benzodiazepine BZRAs) reserved only for patients unable or unwilling to receive CBT-I 1, 2.
Direct Comparison: Why Magnesium Threonate Wins
Magnesium Threonate (L-threonate)
- Objective sleep improvements: Significantly improved deep sleep scores, REM sleep scores, and light sleep time measured by Oura ring tracking 3
- Daytime functioning: Enhanced energy, alertness, mood, and daily productivity 3
- Cognitive benefits: Improved overall cognition, working memory, and reduced cognitive age by 7.5 years 4
- Physiological markers: Reduced resting heart rate and increased heart rate variability (stress reduction markers) 4
- Dosing: 1 gram daily (providing ~144 mg elemental magnesium) for 21 days showed significant effects 3
- Mechanism: Superior brain bioavailability due to its unique ability to cross the blood-brain barrier 3
Magnesium Glycinate (Bisglycinate)
- Modest subjective improvements only: Small effect size (Cohen's d = 0.2) on Insomnia Severity Index scores 5
- Limited benefit: ISI score reduction of -3.9 vs -2.3 for placebo at 4 weeks—clinically marginal 5
- No objective sleep data: Study relied entirely on questionnaires without objective sleep measurements 5
- Dosing: 250 mg elemental magnesium daily 5
- Best responders: May benefit those with low baseline dietary magnesium intake 5
Practical Algorithm for Clinical Use
Step 1: Assess Treatment Appropriateness
- Has the patient tried or been offered CBT-I? If no, refer for CBT-I first 1, 2
- Is the patient refusing or unable to access CBT-I? If yes, consider short-term prescription hypnotics (doxepin 3-6 mg or non-benzodiazepine BZRAs) 1
- Is the patient seeking adjunctive or alternative approaches? Only then consider magnesium supplementation
Step 2: Choose Magnesium Threonate
- Dose: 1 gram magnesium L-threonate daily (approximately 144 mg elemental magnesium)
- Duration: Minimum 21 days to assess response; studied safely up to 6 weeks 3, 4
- Timing: Take in evening, though specific timing not specified in trials
- Expected timeline: Improvements in sleep quality and daytime functioning within 3 weeks 3
Step 3: Monitor Response
- Subjective markers: Sleep quality, morning alertness, daytime energy, mood
- Objective markers: Consider wearable sleep tracking if available (deep sleep, REM sleep duration)
- Safety: Well-tolerated with no significant adverse events reported 3, 4
Critical Caveats and Pitfalls
Do not exceed recommended doses 6. While magnesium is generally safe, excessive intake can cause gastrointestinal distress and, in extreme cases, hypermagnesemia.
Magnesium is not a substitute for evidence-based insomnia treatment. The strongest evidence supports CBT-I, which outperforms pharmacotherapy in long-term outcomes with fewer adverse effects 1. Using magnesium supplements may delay patients from receiving truly effective treatment.
The evidence for magnesium supplements is recent but limited. Both studies on magnesium threonate 3, 4 and the glycinate study 5 are from 2024-2025, representing emerging rather than established evidence. These are single trials requiring replication.
Assess for underlying causes of insomnia before supplementation. Sleep apnea, restless legs syndrome, medication effects, psychiatric conditions, and medical comorbidities require specific treatment, not magnesium supplementation.
Consider baseline magnesium status. The glycinate study suggested better responses in those with lower dietary magnesium intake 5, though this was exploratory. Patients with adequate magnesium intake may see minimal benefit.
Why Threonate Over Glycinate: The Mechanistic Advantage
The superiority of magnesium threonate stems from its unique pharmacokinetics. The threonate carrier specifically enhances brain magnesium levels by facilitating blood-brain barrier penetration 3. This explains why threonate produces objective improvements in sleep architecture (deep and REM sleep) and cognitive function, while glycinate—despite better general bioavailability—shows only modest subjective effects 5, 3, 4.